Guest Editors
Dr. Luigi Liguori
Email: luigi.liguori2@unina.it
Affiliation: Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, 84081, Italy.
Homepage:
Research Interests: Cancer immunotherapy, predictive biomarkers
Summary
Immune checkpoint inhibitor (ICI)-based immunotherapy has revolutionized the management of many types of solid tumors. This novel immunotherapeutic approach has improved the survival outcomes of cancer patients as compared to conventional therapies. However, more than half of treated patients achieve a short-term clinical benefit or rapidly progress since the occurrence of acquired and innate resistance, respectively. Various tumor-intrinsic and tumor-extrinsic mechanisms contributing to ICI resistance have been identified, so far. This special issue aims to gain insight into the key mechanisms underscoring ICI resistance and to explore novel therapeutic strategies to overcome ICI resistance. This special issue will include review articles, case reports, case series, metanalyses, and original research articles.
Keywords
Acquired resistance, CTLA-4, ICI, immunotherapy, innate resistance, PD-1, PD-L1, resistance
Login
Register
Submit a Paper
Propose a Special lssue